Description
Lumefantrine (benflumetol) is created for our class of drug mefloquine on Plasmodium vivax sexual and asexual body a clear killing effect on P. vivax has a good effect to prevent.
- CAS No: 82186-77-4
- Purity: 99%min
- Appearance: Yellow powder
- Application: Antimalarial drugSpecification:
Item Standard Characteristics yellow colored powder Solubility soluble in chloroform Identification IR HPLC Water 0.5% max Residue on ignition 0.1% max Heavy metals 20ppm max Related compounds any single impurity 0.1% max total impurity 0.3% max Residual solvents meet the requirement Assay 98.0-102.0% Total plate count 1000/g max Yeast&mold 100/g max E.Coli Negative Salmonella Negative staphylococci Negative Colifer 10/g max Packaging details:
Packaging details: 25kg/drum with double plastic bags inside; packed in a cardboard drum or fiber HDPE drum. Storage: Stored in a clean, cool, dry area; keep away from moisture and strong, direct light/heat Shelf Life: 5 years if sealed and store away from direct sun light.
Additional Information
The most widely recognized markets for this item incorporate the accompanying nations. If you don’t mind ask with us if your nation or district isn’t recorded:
ASIA: Afghanistan, Israel, Jordan, Pakistan, Russia, Saudi Arabia, Singapore, Syria, Philippines, Turkey, Turkmenistan, Uzbekistan, Yemen, Vietnam, Indonesia, Malaysia, Iran, Tajikistan, and so forth.
AFRICA: South Africa, Uganda, Nigeria, Ghana, Kenya, Mauritius, Botswana, Egypt, Ethiopia, Libya, Sudan, Congo, Gambia, Ivory Coast , and so forth.
NORTH & SOUTH AMERICA: USA, Canada, Panama, Trinidad and Tobago, Costa Rica, Puerto Rico, Dominican Republic, Argentina, Guatemala, Guyana, Peru, Bolivia, Venezuela , Brazil, Bahamas, Ecuador, and so forth .
EUROPE: Austria , Azerbaijan, Belarus, Belgium, Cyprus, Czech Republic, Denmark, France, Georgia, Germany, Hungary, Ireland, Iceland, Netherlands, Norway, Poland, Spain, Sweden, Switzerland, Ukraine, United Kingdom (UK) , Latvia, and so forth.
OCEANIA: Australia, New Zealand, Fiji, and so forth.
